Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Healthcare Biotechnology
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Resverlogix Corp > Apabetalone’s Beneficial Effects on COVID-19 Published in ..
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(3)
•••
Post by seanj1on Mar 18, 2021 9:09pm
320 Views
Post# 32835282

Apabetalone’s Beneficial Effects on COVID-19 Published in ..

Apabetalone’s Beneficial Effects on COVID-19 Published in ..
Well by the time this gets to the final hurdle, Covid 19 will be a thing of the past as far as pandemic goes, eventhough it will be around for a while like a flu. Also the current management team is not capable to get it done.  Apabetalone's potential in treating other similar disease will be the potential success of the company but we will not get there with the current  management team. McCaffrey is getting paid his annual hefty salary no matter what, so he likes his cozy job and BOD...

https://ca.wallmine.com/tsx/rvx/officer/2073968/donald-mccaffrey

What is the salary of Donald McCaffrey?

As the Chairman of the Board, President, Chief Executive Officer, and Secretary of Resverlogix, the total compensation of Donald McCaffrey at Resverlogix is CAD$1,954,160. There are no executives at Resverlogix getting paid more.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities